People · Operator

Adi Mor

Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology

1
Companies
1
Filings
$55.4M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Chemomab Therapeutics Ltd.BiotechnologySeries C$55.4M$86.6M2024
Operator network

Adi Mor at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Arnon Aharon · 2 companies · 1 sharedArnon AharonMATTHEW FRANKEL · 2 companies · 1 sharedMATTHEW FRANKELNIssim Darvish · 2 companies · 1 sharedNIssim DarvishStephen P Squinto · 2 companies · 1 sharedStephen P SquintoAdi Mor George · 1 companies · 1 sharedAdi Mor GeorgeAlan Charles Moses · 1 companies · 1 sharedAlan Charles MosesClaude Charles Nicaise · 1 companies · 1 sharedClaude Charles Ni…Jill Harris Quigley · 1 companies · 1 sharedJill Harris Quigl…Joel Michael Maryles · 1 companies · 1 sharedJoel Michael Mary…Moses Charles Alan · 1 companies · 1 sharedMoses Charles AlanNeil Harris Cohen · 1 companies · 1 sharedNeil Harris CohenNissim Charles Darvish · 1 companies · 1 sharedNissim Charles Da…Sigal Fatal · 1 companies · 1 sharedSigal FatalSigal Fattal · 1 companies · 1 sharedSigal FattalChemomab Therapeutics Ltd. · $55.4M raisedChemomab Therapeutics…Adi MorAM
Adi Mor Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Adi Mor on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
MATTHEW FRANKEL12
NIssim Darvish12
Stephen P Squinto12
Arnon Aharon12
Alan Charles Moses11
Claude Charles Nicaise11
Adi Mor George11
Joel Michael Maryles11
Nissim Charles Darvish11
Sigal Fatal11
Moses Charles Alan11
Neil Harris Cohen11
Jill Harris Quigley11
Sigal Fattal11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.